PD-1 pathway blockade in combination with chemotherapy has emerged as a treatment paradigm for patients with resectable lung cancer, but insights into predictive biomarkers and mechanisms of immune responses are lacking. A study uses spatial transcriptomic methods to identify patterns within the tumor microenvironment associated with response.
This is a preview of subscription content, access via your institution
Access options
Access through your institution
Change institution
Buy or subscribe
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Learn more
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Learn more
Buy this article
Purchase on SpringerLink
Instant access to full article PDF
Buy now
Prices may be subject to local taxes which are calculated during checkout
Additional access options:
Log in
Learn about institutional subscriptions
Read our FAQs
Contact customer support
Fig. 1: The composition and organization of the TME reflect the interaction of numerous features.
References
Passaro, A., Attili, I. & de Marinis, F. J. Clin. Oncol. 40, 2871–2877 (2022).
ArticleCASPubMedGoogle Scholar
Yan, Y. et al. Nat. Genet.https://doi.org/10.1038/s41588-024-01998-y (2024).
ArticlePubMedPubMed CentralGoogle Scholar
Holder, A. M. et al. Nat. Rev. Cancer 24, 498–512 (2024).
ArticleCASPubMedGoogle Scholar
Ravi, A. et al. Nat. Genet. 55, 807–819 (2023).
ArticleCASPubMedPubMed CentralGoogle Scholar
Cristescu, R. et al. Science 362, eaar3593 (2018).
ArticlePubMedPubMed CentralGoogle Scholar
Litchfield, K. et al. Cell 184, 596–614.e14 (2021).
ArticleCASPubMedPubMed CentralGoogle Scholar
Reschke, R. et al. J. Immunother. Cancer 9, e003521 (2021).
ArticlePubMedPubMed CentralGoogle Scholar
Chen, J. H. et al. Nat. Immunol. 25, 644–658 (2024).
ArticleCASPubMedGoogle Scholar
Bill, R. et al. Science 381, 515–524 (2023).
ArticleCASPubMedPubMed CentralGoogle Scholar
Hoch, T. et al. Sci. Immunol. 7, eabk1692 (2022).
ArticleCASPubMedGoogle Scholar
Schulz, D. et al. Cell Syst. 6, 25–36.e5 (2018).
ArticleCASPubMedPubMed CentralGoogle Scholar
Pillai, R., Hayashi, M., Zavitsanou, A.-M. & Papagiannakopoulos, T. Cancer Discov. 12, 625–643 (2022).
ArticleCASPubMedPubMed CentralGoogle Scholar
Ricciuti, B. et al. J. Thorac. Oncol. 17, 399–410 (2022).
ArticleCASPubMedGoogle Scholar
Ricciuti, B. & Garassino, M. C. J. Thorac. Oncol. 19, 877–882 (2024).
ArticleCASPubMedGoogle Scholar
Schumacher, T. N. & Thommen, D. S. Science 375, eabf9419 (2022).
ArticleCASPubMedGoogle Scholar
Download references
Author information
Authors and Affiliations
Department of Pathology, Northwestern University, Chicago, IL, USA
Jonathan H. Chen
Division of Hematology/Oncology, Massachusetts General Hospital, Boston, MA, USA
Justin F. Gainor
Harvard Medical School, Boston, MA, USA
Justin F. Gainor
Authors
Jonathan H. Chen
View author publications
You can also search for this author in PubMedGoogle Scholar
2. Justin F. Gainor
View author publications
You can also search for this author in PubMedGoogle Scholar
Corresponding author
Correspondence to Justin F. Gainor.
Ethics declarations
Competing interests
J.H.C. receives research support from the Society for Immunotherapy of Cancer AstraZeneca fellowship and a sponsored research agreement with Calico labs and previously with Novartis. J.H.C. consults for Merck and has also received a speaking honorarium from the Society for Interventional Oncology and has non-paid technology materials transfer agreements with NanoString and Vizgen. J.F.G. has served as a compensated consultant for Amgen, AstraZeneca, Mariana Therapeutics, Mirati Therapeutics, Merus Pharmaceuticals, Nuvalent, Pfizer, Novocure, AI Proteins, Novartis, Silverback Therapeutics, Sanofi, Blueprint Medicines, Bristol Myers Squibb, Genentech, Gilead Sciences, ITeos Therapeutics, Jounce Therapeutics, Karyopharm Therapeutics, Lilly/Loxo, Merck, Moderna Therapeutics and Takeda; has received honorarium from Novartis, Merck, Novartis, Pfizer and Takeda; has received institutional research funding from Adaptimmune, Alexo Therapeutics, AstraZeneca, Blueprint Medicines, Bristol Myers Squibb, Genentech, Jounce Therapeutics, Merck, Moderna Therapeutics, Novartis, NextPoint Therapeutics and Palleon Pharmaceuticals; has received research support from Novartis, Genentech and Takeda and has equity in AI Proteins; and has an immediate family member who has equity in and is employed by Ironwood Pharmaceuticals.
Rights and permissions
Reprints and permissions
About this article
Check for updates. Verify currency and authenticity via CrossMark
Cite this article
Chen, J.H., Gainor, J.F. Spatial biology captures the effects of neoadjuvant chemo-immunotherapy in lung cancer. Nat Genet (2024). https://doi.org/10.1038/s41588-024-01992-4
Download citation
Published:10 December 2024
DOI:https://doi.org/10.1038/s41588-024-01992-4
Share this article
Anyone you share the following link with will be able to read this content:
Get shareable link
Sorry, a shareable link is not currently available for this article.
Copy to clipboard
Provided by the Springer Nature SharedIt content-sharing initiative